Try it
Radiology · Radiotherapy: radiosensitisers
Sample itemWhich drug is commonly given concurrently with radiotherapy for locally advanced cervical and head and neck cancer to improve local control?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
A. Cisplatin
Cisplatin acts as a radiosensitiser by inhibiting DNA repair and gives a survival benefit in concurrent chemoradiotherapy for cervix and head and neck cancer. Amifostine is a protector. Tamoxifen is hormonal and octreotide is a somatostatin analogue.
Option by option
A. Cisplatin (correct)
Correct. Concurrent cisplatin improves outcomes.
B. Tamoxifen
Tamoxifen is endocrine therapy.
C. Octreotide
Octreotide is a hormone analogue and not a radiosensitiser.
D. Amifostine
Amifostine protects normal tissue.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Radiology questions
- NeuroimagingWhat is the first investigation of choice in suspected acute subarachnoid haemorrhage?
- Cardiac imagingA 'boot-shaped' heart (coeur en sabot) on a chest radiograph is typical of:
- Musculoskeletal imagingA 'bamboo spine' on a plain radiograph is characteristic of:
- Paediatric radiologyThe 'double bubble' sign on an abdominal radiograph of a newborn suggests: